- 4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet AMD) patient populations based on longest available follow-up data
- In broad population (Phase 2b), 70% injection-free through 52 weeks
- In severe population (Phase 1/2a), 83% overall reduction in annualized injections through 52 weeks
- 4D-150 continues to be safe and well tolerated with intraocular inflammation (IOI) profile numerically similar (2.8% transient 1+ vitreous cells) to approved anti-VEGF agents
- 4FRONT Phase 3 program designed to maximize 4D-150's potential, including probabilities of clinical, regulatory and commercial success across global markets
- Corporate webcast to be held on September 18, 2024 at 4:15 p.m. ET
4DMT Highlights Clinical Activity For 4D-150 And Design Of 4FRONT Phase 3 Program At 4D-150 Wet AMD Development Day
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.